IAG CEO Dr. Olga Kubassova to Speak on Panel at Biotech Investment Showcase, 22-23 May, London, UK
Dr. Olga Kubassova, IAG CEO will be speaking on a panel addressing leading-edge funding, investment and partnering models at the Biotech Investment Showcase and Start-Up Slam. Dr. Kubassova will discuss the challenges biotechnology companies face in the industry and will explain IAG’s unique approach to solving these problems.
Dr. Diana Roettger, Head of Scientific and Medical Affairs and Lead Bio-Partnering analyst will also attend the conference to meet with different biotechnology companies and identify potential opportunities for strategic financial investment and collaboration.
To schedule a meeting or learn more about Dr. Kubassova’s Panel Discussion, please email email@example.com
About Biotech Investment Showcase and Start-up Slam
The 2018 Biotech Investment showcase is the UK and Europe’s most focused and leading-edge funding, investment and partnering forum in the biotech sector, hosting over 200 attendees. Leading VC funds, investors, hedge funds, emerging successful biotech spinoffs, early stage biotech discovery and clinical companies and KOLs in the sector will be attending this one of a kind showcase event on the 22nd & 23rd May 2018 in London. The event will help to identify key technological and scientific investment areas and offers a unique networking, partnering and business development opportunity for those involved. To find out more about this conference click here.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com